ATE542896T1 - Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung - Google Patents

Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung

Info

Publication number: ATE542896T1
Authority: AT; Austria
Prior art keywords: dpp; protein hydrolyzate; protein hydrolysate; inhibiting peptides; enriched
Prior art date: 2004-12-23

Application number

AT05809074T

Other languages

English (en)

Inventor

Jan-Willem Pieter Boots

Original Assignee

Campina Nederland Holding Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-23

Filing date

2005-11-30

Publication date

2012-02-15

2005-11-30 Application filed by Campina Nederland Holding Bv filed Critical Campina Nederland Holding Bv

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE542896T1 publication Critical patent/ATE542896T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
239000003531 protein hydrolysate Substances 0.000 title abstract 4
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title abstract 3
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title abstract 3
230000002401 inhibitory effect Effects 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108010009736 Protein Hydrolysates Proteins 0.000 abstract 3
208000008589 Obesity Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
235000013361 beverage Nutrition 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
235000013305 food Nutrition 0.000 abstract 1
239000000413 hydrolysate Substances 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/202—Casein or caseinates
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/548—Vegetable protein
- A23V2250/5488—Soybean protein

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Polymers & Plastics (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Food Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)

AT05809074T 2004-12-23 2005-11-30 Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung ATE542896T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04078502		2004-12-23
PCT/NL2005/050056 WO2006068480A2 (en)	2004-12-23	2005-11-30	Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use

Publications (1)

Publication Number	Publication Date
ATE542896T1 true ATE542896T1 (de)	2012-02-15

Family

ID=36602170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05809074T ATE542896T1 (de)	2004-12-23	2005-11-30	Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung

Country Status (9)

Country	Link
US (2)	US8273710B2 (de)
EP (1)	EP1831361B1 (de)
JP (1)	JP5068174B2 (de)
KR (1)	KR101331777B1 (de)
AT (1)	ATE542896T1 (de)
DK (1)	DK1831361T3 (de)
ES (1)	ES2381118T3 (de)
TW (1)	TWI421089B (de)
WO (1)	WO2006068480A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2381118T3 (es)	2004-12-23	2012-05-23	Campina Nederland Holding B.V.	Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso
EP1907412B1 (de) *	2005-06-30	2012-04-11	Campina Nederland Holding B.V.	Das angiotensin-converting enzyme inhibierende peptide
JP2009517464A (ja) *	2005-11-30	2009-04-30	カンピーナネーダーランドホールディングビー．ブイ．	グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
EP1840133A1 (de) *	2006-03-29	2007-10-03	Global Biotech Development Corp. Ltd.	Neue immunomodulierende Oligopeptide
JP5645360B2 (ja) *	2006-04-21	2014-12-24	株式会社明治	ジペプチドを有効成分として含有する組成物
EP2017283A4 (de) *	2006-04-28	2015-12-30	Megmilk Snow Brand Co Ltd	Peptide
JP2008189637A (ja) *	2007-02-08	2008-08-21	Snow Brand Milk Prod Co Ltd	自己免疫疾患予防剤
GB2451858A (en) *	2007-08-15	2009-02-18	Sergiy Konovchuk	Methods of reducing body fat and treating obesity
WO2009046829A2 (en) *	2007-09-11	2009-04-16	Mondobiotech Laboratories Ag	Casoxin d as a therapeutic agent
WO2009128713A1 (en) *	2008-04-14	2009-10-22	Newtricious B.V.	Egg protein hydrolysates
DE102008062136B4 (de) *	2008-12-16	2012-05-03	Kamamed Ug	Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
JP5622593B2 (ja) *	2009-02-02	2014-11-12	国立大学法人京都大学	ペプチドを含む医薬または食品
JP5735734B2 (ja) *	2009-04-16	2015-06-17	雪印メグミルク株式会社	脂質代謝改善剤
JP2011084485A (ja) *	2009-10-13	2011-04-28	Snow Brand Milk Prod Co Ltd	脂肪蓄積抑制剤
US20120322726A1 (en) *	2010-02-24	2012-12-20	Morinaga Milk Industry Co., Ltd.	Therapeutic agent for eating disorders
WO2011141903A1 (en) *	2010-05-12	2011-11-17	Mapi Pharma Holdings (Cyprus) Limited	Polymorphs of alogliptin benzoate
US9657086B2 (en) *	2010-08-24	2017-05-23	Wuhan Jiushengtang Bioengineering Co., Ltd	Whole egg protein peptides, preparation method and use thereof
JP5976004B2 (ja) *	2012-03-09	2016-08-23	森永乳業株式会社	ジペプチジルペプチダーゼ−ｉｖ阻害剤
JP5832049B2 (ja) *	2012-03-09	2015-12-16	森永乳業株式会社	ジペプチジルペプチダーゼ−ｉｖ阻害剤
WO2014060495A1 (en) *	2012-10-19	2014-04-24	Dsm Ip Assets B.V.	Process for the production of an infant formula
CN103232526B (zh) *	2012-12-12	2015-06-24	上海交通大学	一种生物活性多肽lplp及其制备和应用
US9345727B2 (en)	2013-03-15	2016-05-24	Mead Johnson Nutrition Company	Nutritional compositions containing a peptide component and uses thereof
US8889633B2 (en)	2013-03-15	2014-11-18	Mead Johnson Nutrition Company	Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9138455B2 (en) *	2013-03-15	2015-09-22	Mead Johnson Nutrition Company	Activating adiponectin by casein hydrolysate
US9352020B2 (en) *	2013-03-15	2016-05-31	Mead Johnson Nutrition Company	Reducing proinflammatory response
US9289461B2 (en)	2013-03-15	2016-03-22	Mead Johnson Nutrition Company	Reducing the risk of autoimmune disease
US9345741B2 (en)	2013-03-15	2016-05-24	Mead Johnson Nutrition Company	Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
MY165122A (en) *	2013-06-12	2018-02-28	Maruha Nichiro Corp	Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same
CN103483418B (zh) *	2013-09-12	2015-04-01	陈尚武	一种dpp-ⅳ抑制多肽及其应用
US10639334B2 (en) *	2014-01-07	2020-05-05	Mead Johnson Nutrition Company	Pediatric nutritional composition with milk peptides for healthy growth and development
FR3017536B1 (fr) *	2014-02-18	2017-05-26	Univ La Rochelle	Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
JP5872725B1 (ja) *	2015-02-26	2016-03-01	ヤマキ株式会社	鰹節由来のジペプチジルペプチダーゼｉｖ阻害組成物
JP2017031105A (ja) *	2015-08-03	2017-02-09	森永乳業株式会社	食後血糖値の上昇抑制を促進させる剤
CN105341949B (zh) *	2015-10-09	2018-03-27	滨州万嘉生物科技有限公司	一种具有降血糖功能的鱼肉蛋白肽及其制备方法与应用
US11129404B2 (en)	2015-12-28	2021-09-28	Abbott Laboratories	Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof
JP7157043B2 (ja) *	2017-03-03	2022-10-19	森永乳業株式会社	Ｇｌｐ－１分泌促進剤及び組成物
BR112019019256A2 (pt)	2017-03-16	2020-04-14	Microsintesis Inc	moléculas probióticas para reduzir a virulência de patógenos
NZ758166A (en) *	2017-03-16	2024-12-20	Microsintesis Inc	Compositions and methods involving probiotic molecules
CN108314705B (zh) *	2018-01-26	2020-07-14	海普诺凯营养品有限公司	具有dpp-iv抑制功能的羊乳清蛋白肽、其制备方法及其应用
CN108935912B (zh) *	2018-06-21	2021-04-23	中国农业大学	一种具有dpp-ⅳ抑制和抗疲劳功能的鱼肉蛋白肽及其制备方法
JP7068942B2 (ja) *	2018-06-25	2022-05-17	サンスター株式会社	トリペプチド含有組成物
WO2021083958A1 (en) *	2019-10-29	2021-05-06	Specialites Pet Food	Novel peptides inducing satiety
CN114621320B (zh) *	2020-12-14	2024-05-24	清华大学	一种可用于减缓glp-1酶解的短肽及其组合物
WO2022186290A1 (ja) *	2021-03-02	2022-09-09	森永乳業株式会社	ジペプチジルペプチダーゼ－ｉｖ阻害剤
CN113035291B (zh) *	2021-04-08	2022-04-05	广东药科大学	计算机辅助药物设计dpp-iv抑制肽的方法、dpp-iv抑制肽及其应用
CN113480605A (zh) *	2021-07-27	2021-10-08	中国海洋大学	一种牦牛乳酪蛋白dpp-iv抑制肽及其筛选方法
JP2023069271A (ja)	2021-11-05	2023-05-18	住友化学株式会社	Ｄｐｐ－４阻害剤およびその製造方法。
CN114686551B (zh) *	2022-03-16	2023-08-08	江南大学	一种豌豆蛋白源dpp-iv抑制肽及其筛选方法
CN114836491B (zh) *	2022-05-30	2023-03-14	广州恒雅生物化工有限公司	一种抗老亮肤的肌肽制备方法及其在化妆品的应用
JPWO2024038888A1 (de) *	2022-08-19	2024-02-22
CN115252759A (zh) *	2022-08-24	2022-11-01	四川大学华西第二医院	酸奶衍生多肽在制备延缓端粒缩短药物及抗衰老药物中的应用
CN116284234B (zh) *	2023-02-09	2024-11-08	昆明理工大学	一种驼乳源小分子肽及其应用
CN117598389A (zh) *	2023-11-13	2024-02-27	大连工业大学	一种具有增强免疫功能的酪蛋白水解物及其制备方法
CN118620029B (zh) *	2024-05-27	2024-12-20	合肥工业大学	一种干腌火腿源dpp-iv抑制肽及其制备、鉴定方法和应用
CN118894920B (zh) *	2024-10-09	2025-04-04	澳优乳业（中国）有限公司	一种具有降血糖作用的功能肽及制备方法和应用
CN120098106B (zh) *	2025-05-08	2025-08-22	华南理工大学	一种酪蛋白源降血糖肽及其应用
CN120718130B (zh) *	2025-08-15	2025-12-30	杭州康源食品科技有限公司	一种促钙吸收利用的酪蛋白源七肽及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681586A (en)	1989-03-23	1997-10-28	Gordon; Arthur L.	Enzyme-modified soy and soy/casein combination healing compositions
JP3119674B2 (ja) *	1991-02-15	2000-12-25	日本合成化学工業株式会社	新規ペプチド、その製造法及び用途
DE4211878C2 (de)	1992-04-09	1995-04-20	Ralf Dr Med Kluge	Mittel zur Behandlung der Multiplen Sklerose
WO1994011689A1 (en) *	1992-11-19	1994-05-26	Yu Tom Yen Shing	Paper sheet coating apparatus with gas streams drying
US5405637A (en)	1993-06-30	1995-04-11	Bristol-Myers Squibb Company	Milk protein partial hydrolysate and infant formula containing same
JP3665663B2 (ja) *	1994-08-02	2005-06-29	カルピス株式会社	血圧降下剤及びその製造法
JP2000515139A (ja)	1996-07-17	2000-11-14	ニュートラコープ・サイエンティフィック・インク	食欲の抑制
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CA2296311A1 (en) *	1999-01-28	2000-07-28	Universite Laval	Enzymatic hydrolysate of milk proteins
EP1034704A1 (de)	1999-03-12	2000-09-13	Societe Des Produits Nestle S.A.	Nahrungszusammensetzung insbesondere für die spezifische gastrointestinale Reifung in frühgeborenen Säugetieren
AU5382200A (en) *	1999-06-15	2001-01-02	University Health Network	Muc1 ligands
US20040152745A1 (en) *	1999-11-12	2004-08-05	Guilford Pharmaceuticals, Inc.	Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
GB9927603D0 (en)	1999-11-22	2000-01-19	Nestle Sa	Use of a milk protein hydrolysate in the treatment of diabetes
AU2000269178A1 (en) *	2000-08-17	2002-02-25	The University Of Texas System	Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators
ATE328491T1 (de)	2000-10-24	2006-06-15	Campina Melkunie Bv	Peptiden reich an cystein und/oder glycin
KR20030085112A (ko)	2000-12-07	2003-11-03	디에스엠 아이피 어셋츠 비.브이.	카르복시 말단 프롤린 잔기를 갖는 펩티드가 풍부한단백질 가수분해물
WO2002071854A1 (en) *	2001-03-09	2002-09-19	Unilever N.V.	Fermented milk product
JP2002284668A (ja) *	2001-03-26	2002-10-03	Cosmo Products Kk	クスミの予防・治療剤
FR2825004B1 (fr)	2001-05-22	2005-02-11	Bio Springer	Produit dietetique satiant
CN1688599A (zh)	2001-06-27	2005-10-26	前体生物药物股份有限公司	二肽基肽酶iv抑制剂的新用途
WO2003035051A2 (en)	2001-10-19	2003-05-01	Inhale Therapeutic Systems, Inc.	The use of proton sequestering agents in drug formulations
US20030165574A1 (en)	2002-03-01	2003-09-04	Ward Loren Spencer	Compositions and methods for treatment of body weight conditions
AU2003228744A1 (en) *	2002-04-29	2003-11-17	The Ohio State University	Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
EP1367065B1 (de)	2002-05-27	2008-07-30	Nestec S.A.	Säurelösliche Proteine aus Casein-Micellen
AU2003236689A1 (en)	2002-06-04	2003-12-19	Dsm Ip Assets B.V.	Protein hydrolysate rich in tripeptides
GB0213612D0 (en)	2002-06-13	2002-07-24	Novartis Nutrition Ag	Organic compounds
ATE349918T1 (de)	2002-07-01	2007-01-15	Unilever Nv	Zusammensetzung, die ein sättigungsgefühl hervorruft
JP4719465B2 (ja) *	2002-09-04	2011-07-06	ディーエスエムアイピーアセッツビー．ブイ．	インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物
WO2004024177A1 (en)	2002-09-16	2004-03-25	Quest International Services B.V.	Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein
ATE469645T1 (de) *	2002-10-23	2010-06-15	Bristol Myers Squibb Co	Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US20070015269A1 (en) *	2002-11-25	2007-01-18	Michael Hennig	Crystals of DPP-IV
EP1422293A1 (de) *	2002-11-25	2004-05-26	F. Hoffmann-La Roche Ag	Kristallstruktur der Dipeptidylpeptidase iV
ATE477812T1 (de)	2003-02-07	2010-09-15	Campina Bv	Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
GB0310593D0 (en)	2003-05-08	2003-06-11	Leuven K U Res & Dev	Peptidic prodrugs
CA2558155A1 (en) *	2004-03-01	2005-09-09	Zvi Sidelman	Casein derived peptides and therapeutic uses thereof
JP2008500304A (ja)	2004-05-27	2008-01-10	カンピーナネーダーランドホールディングビー．ブイ．	Ｄｐｐ−ｉｖ媒介症状の予防及び／又は治療用の薬剤製造のためのタンパク質加水分解物の使用
NZ552140A (en)	2004-07-12	2009-02-28	Dsm Ip Assets Bv	Blood pressure lowering protein hydrolysates
ES2381118T3 (es)	2004-12-23	2012-05-23	Campina Nederland Holding B.V.	Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso
JP2009517464A (ja)	2005-11-30	2009-04-30	カンピーナネーダーランドホールディングビー．ブイ．	グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用

2005
- 2005-11-30 ES ES05809074T patent/ES2381118T3/es not_active Expired - Lifetime
- 2005-11-30 EP EP05809074A patent/EP1831361B1/de not_active Expired - Lifetime
- 2005-11-30 WO PCT/NL2005/050056 patent/WO2006068480A2/en not_active Ceased
- 2005-11-30 AT AT05809074T patent/ATE542896T1/de active
- 2005-11-30 DK DK05809074.7T patent/DK1831361T3/da active
- 2005-11-30 US US11/722,667 patent/US8273710B2/en not_active Expired - Fee Related
- 2005-11-30 JP JP2007548113A patent/JP5068174B2/ja not_active Expired - Fee Related
- 2005-11-30 KR KR1020077014235A patent/KR101331777B1/ko not_active Expired - Fee Related
- 2005-12-01 TW TW094142261A patent/TWI421089B/zh not_active IP Right Cessation
2012
- 2012-09-14 US US13/620,474 patent/US20130096074A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1831361A2 (de)	2007-09-12
US8273710B2 (en)	2012-09-25
KR101331777B1 (ko)	2013-11-21
JP2008525430A (ja)	2008-07-17
US20090075904A1 (en)	2009-03-19
WO2006068480A3 (en)	2007-01-04
TW200621283A (en)	2006-07-01
WO2006068480A2 (en)	2006-06-29
DK1831361T3 (da)	2012-05-14
EP1831361B1 (de)	2012-01-25
TWI421089B (zh)	2014-01-01
KR20070101253A (ko)	2007-10-16
ES2381118T3 (es)	2012-05-23
US20130096074A1 (en)	2013-04-18
JP5068174B2 (ja)	2012-11-07

Publication	Publication Date	Title
ATE542896T1 (de)	2012-02-15	Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung
Tacias-Pascacio et al.	2020	Use of Alcalase in the production of bioactive peptides: A review
Hatanaka et al.	2012	Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran
Le Gouic et al.	2018	Bioactive peptides from fish protein by-products
Tulipano et al.	2015	Characterisation of the potential of β-lactoglobulin and α-lactalbumin as sources of bioactive peptides affecting incretin function: In silico and in vitro comparative studies
Iwaniak et al.	2018	Peptides derived from foods as supportive diet components in the prevention of metabolic syndrome
WO1995025749A3 (en)	1995-12-07	Eating suppressant peptides
CY1111322T1 (el)	2015-08-05	Προϊοντα υδρολυσης πρωτεϊνων εμπλουτισμενα σε πεπτιδια που εχουν ενα καρβοξυ-τερματικο υπολειμμα προλινης
PL1898724T3 (pl)	2011-02-28	Preparat odżywczy dla niemowląt z hydrolizowanymi białkami
DE60204714D1 (de)	2005-07-21	Pharmakologische nahrungszusammensetzung zur nahrungsergängzung und nährwertverbesserung
DE602004023210D1 (de)	2009-10-29	Biologisch nicht-abbaubares peptid, inhibitor des angiotensinumwandelnden enzyms, arzneimittel und funktionelles nahrungsmittel
ATE366317T1 (de)	2007-07-15	Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
WO2010000801A3 (de)	2010-12-09	Molkenproteinhydrolysate enthaltend tryptophanhaltige peptide aus alpha-lactalbumin und deren verwendung
Zhang et al.	2019	Purification and identification of dipeptidyl peptidase IV and angiotensin-converting enzyme inhibitory peptides from silver carp (Hypophthalmichthys molitrix) muscle hydrolysate
Nongonierma et al.	2017	Response surface methodology applied to the generation of casein hydrolysates with antioxidant and dipeptidyl peptidase IV inhibitory properties
UA72915C2 (uk)	2005-05-16	Поживна ентеральна композиція, призначена для підтримки зростання та дозрівання недорозвинених шлунково-кишкових трактів у молодих ссавців та її застосування
WO2006000350A3 (en)	2006-07-13	Cosmetic compositions containing protein hydrolysates
TW200940080A (en)	2009-10-01	Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products
Lydon et al.	1992	Nucleotide and primary amino acid sequence of porcine lactoferrin
ATE362372T1 (de)	2007-06-15	Verwendung von mindestens einem peptid des alpha- s2 caseins mit ace hemmender wirkung zur vorbereitung von arzneimitteln und nahrungsmitteln
WO2005002600A3 (en)	2005-03-31	Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus
GB9917725D0 (en)	1999-09-29	Peptides
WO2006028561A3 (en)	2007-08-30	Novel purified fabi polypeptides from fransicella tularensis
Dong-Min et al.	1992	Angiotensin-I converting enzyme inhibitory activity of enzymatic hydrolysates of mackerel muscle protein
Tan et al.	2022	Tenebrio molitor proteins-derived DPP-4 inhibitory peptides: preparation, identification, and molecular binding mechanism. Foods. 2022; 11 (22): 3626